Summit addresses need for innovation

Share this article:
Pharmaceutical e-marketing experts called for more innovation in online efforts as the Web enters its second and third incarnations.

“We need to add what is changing to our planning process,” said Paul Ivans, president, Evolution Road Consulting, at IIR's 6th annual ePharma Summit in Philadelphia. “Strategic and tactical planning must include innovation,” he added.

Ivans was among a number of online experts to address 250 e-marketers at the event. Topics of discussion included the rise of the empowered consumer, growth of user-generated content and ways to drive ROI.

 The event featured a thought leader panel discussion including e-marketers from Genentech, Novartis, Lilly and Wyeth.

“A great Web site user experience will result in the holy grail of better patient outcomes and high ROI,” said Frank Visconti, associate director, marketing, at Novartis Pharmaceuticals.

Ben Lei, senior manager, e-marketing at Genentech said that information needs to be easier for consumers to find.

“We need to remove the clutter,” Lei said.

Amy Chafin, specialty therapeutic area marketing manager at Lilly, said her firm is working on finding the right mix through an integration of “sales force, e-detailing, mobile technology and word-of-mouth marketing.”

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Channel

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...